It has been demonstrated that EZH2 interacts with the NF-κB transcription factors, RelA and RelB, to activate pro-inflammatory genes in several cancer types, suggesting that the NF-κB target gene signature is positively regulated by EZH2 [40]. The gene discussed is RELB; the disease is cancer.